CYP24A1 and toxoplasmosis: Additionally, the diverse inhibitory profiles of sulfonamide derivatives (1–24) and clinically used drugs (AAZ–HCT) against Tg_CA and human isoforms (hCA I and II) provided critical insights into their potential for treating toxoplasmosis.